Literature DB >> 10430788

Broad spectrum drug identification directly from urine, using liquid chromatography-tandem mass spectrometry.

R L Fitzgerald1, J D Rivera, D A Herold.   

Abstract

BACKGROUND: Currently the rate-limiting step for mass spectrometric analysis of drugs in biological samples is sample preparation. Many gas chromatography/mass spectrometry (GC/MS) methods are specific for a certain class of compounds, requiring extraction and/or derivatization before analysis. The purpose of this study was to develop a broad spectrum liquid chromatography/mass spectrometry (LC/MS) procedure that allowed for direct analysis of urine specimens with potential for quantitative analysis.
METHODS: We modified a commercially available column-switching instrument, the REMEDi HS from Bio-Rad Diagnostics, to make it compatible with atmospheric pressure ionization. The system we developed was based on electrospray ionization and used three LC columns to extract, purify, and separate drugs directly from urine specimens. Drugs and metabolites were tentatively identified on the basis of retention times and (M+H)(+) ions. Tandem mass spectrometry (MS/MS) was used to confirm the qualitative identification of suspected drugs, using data-dependent acquisition. For quantitative analysis, the cocaine metabolite benzoylecgonine was analyzed using isotope dilution and selected reaction monitoring.
RESULTS: Seventeen basic drugs from a variety of classes of compounds were identified directly from urine without the need for prior sample extraction, using LC and MS/MS. Quantitative analysis was demonstrated for benzoylecgonine. When benzoylecgonine-d(3) was used as the internal standard, the method was linear from 30 to 10 000 microgram/L (range tested). At these concentrations, the within-run accuracy was +/- 10% of the target concentration, with CVs <10%. Analytical results by LC/MS/MS compared favorably with GC/MS values for 50 benzoylecgonine-containing specimens and for 25 negative specimens.
CONCLUSIONS: The ability to directly analyze urine for a wide variety of drug classes, combined with the sensitivity and specificity of LC/MS/MS makes this technique attractive for many clinical, forensic, and biotechnology applications.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10430788

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  6 in total

1.  Principles and applications of liquid chromatography-mass spectrometry in clinical biochemistry.

Authors:  James J Pitt
Journal:  Clin Biochem Rev       Date:  2009-02

2.  Performance evaluation of three liquid chromatography mass spectrometry methods for broad spectrum drug screening.

Authors:  Kara L Lynch; Autumn R Breaud; Hilde Vandenberghe; Alan H B Wu; William Clarke
Journal:  Clin Chim Acta       Date:  2010-06-09       Impact factor: 3.786

3.  Common degradative pathways of morpholine, thiomorpholine, and piperidine by Mycobacterium aurum MO1: evidence from (1)H-nuclear magnetic resonance and ionspray mass spectrometry performed directly on the incubation medium.

Authors:  B Combourieu; P Besse; M Sancelme; J P Godin; A Monteil; H Veschambre; A M Delort
Journal:  Appl Environ Microbiol       Date:  2000-08       Impact factor: 4.792

Review 4.  How to Screen for Non-Adherence to Antihypertensive Therapy.

Authors:  Pankaj Gupta; Prashanth Patel; Robert Horne; Heather Buchanan; Bryan Williams; Maciej Tomaszewski
Journal:  Curr Hypertens Rep       Date:  2016-12       Impact factor: 5.369

5.  Screening for non-adherence to antihypertensive treatment as a part of the diagnostic pathway to renal denervation.

Authors:  P Patel; P K C Gupta; C M J White; A G Stanley; B Williams; M Tomaszewski
Journal:  J Hum Hypertens       Date:  2015-10-08       Impact factor: 3.012

6.  High rates of non-adherence to antihypertensive treatment revealed by high-performance liquid chromatography-tandem mass spectrometry (HP LC-MS/MS) urine analysis.

Authors:  Maciej Tomaszewski; Christobelle White; Prashanth Patel; Nicholas Masca; Ravi Damani; Joanne Hepworth; Nilesh J Samani; Pankaj Gupta; Webster Madira; Adrian Stanley; Bryan Williams
Journal:  Heart       Date:  2014-04-02       Impact factor: 5.994

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.